Potential performance of environmental friendly application of ORC and Flash technology in geothermal power plants

The successful exploitation of geothermal energy for power production relies on to the availability of nearly zero emission and efficient technologies, able to provide flexible operation. It can be realized with the binary cycle technology. It consists of a closed power cycle coupled to a closed geothermal loop, whereby the closed power cycle is generally accomplished by means of an organic Rankine cycle (in a few cases the Kalina cycle has been adopted). The confinement of the geothermal fluid in a closed loop is an important advantage from the environmental point of view: possible pollutants contained in the geothermal fluid are not released into the ambient and are directly reinjected underground. Although a well-established technology in the frame of geothermal applications, the adoption of the binary cycle technology is at the moment typically confined to the exploitation of medium-low temperature liquid geothermal reservoirs, generally between 100-170°C. The important advantages of the binary cycle technology from the environmental point of view suggest nevertheless that it is worthwhile to investigate whether the application range could be extended to higher temperature reservoirs, and up to which extent. Moreover, the paper investigates the effect of an increasing CO2content in the geothermal fluid. The paper compares in a convenient high temperature range of the geothermal source the performance of a properly optimized geothermal ORC plant, with the performance of a modified flash plant, whereby the geothermal steam enters a turbine, and the CO2stream is separated, compressed and finally reinjected. An environmentally friendly working fluid, recently introduced in the market, is considered in the ORC optimization process. The performance comparison will involve the assessment of plant net power. As far as the calculations are concerned, the geothermal fluid is assumed to be a mixture of water and possibly CO2. The auxiliary power consumption is properly accounted for: beyond cooling auxiliaries, a submersible well pump for the ORC plant and a gas compressor for the reinjection of the non-condensable gases in the flash plant are considered

Primary Hodgkin lymphoma of the lung arising with hemoptysis and pulmonary consolidation: a case report.

Classic Hodgkin lymphomas are neoplasms originating from lymphoid tissue. Primary extranodal classic Hodgkin lymphoma (PE-cHL) of the lung is rare. A 37-year-old Caucasian male was referred to our hospital for recurrent episodes of hemoptysis, cough and bronchitis. A CT scan showed a massive left upper lung consolidation, which was positive at the PET scan. After several inconclusive tests and no benefit from medical therapies, the patient underwent a left upper lobectomy; pathology report showed a classical type Hodgkin lymphoma with no lymph-nodes involvement. Four cycles of adjuvant chemotherapy were administered with no toxicity. At the last follow up 14 months after surgery, the patient is alive and free from disease. Primary extranodal classical Hodgkin lymphoma of the lung is a rare entity, but it should be considered as a differential diagnosis in young patients with pulmonary consolidation even without systemic symptoms

Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.

New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasmacells (PCs) represent attractive new therapeutic targets. The endothelin-1(EDN1) axis, consisting of EDN1 acting through EDN-receptor A(EDNRA) and B (EDNRB), was previously shown to be overexpressed inseveral tumours, including MM. However, there is incomplete understand-ing of how EDN1 axis regulates MM growth and response to therapy.Besides EDNRA, the majority of MM cell lines and primary malignant PCsexpress high levels of EDNRB and release EDN1. Similarly, bone-marrowmicroenvironment cells also secrete EDN1. Investigating the extent of epi-genetic dysregulation of EDNRB gene in MM, we found that hypermethyla-tion of EDNRB promoter and subsequent down-regulation of EDNRB genewas observed in PCs or B lymphocytes from healthy donors compared toEDNRB-expressing malignant PCs. Pharm acological blockade with the dualEDN1 receptor antagonist bosentan decreased cell viability and MAPK acti-vation of U266 and RPMI-8226 cells. Interestingly, the combination ofbosentan and the proteasome inhibitor bortezomib, currently approved forMM treatment, resulted in synergistic cytotoxic effects. Overall, our datahas uncovered EDN1-mediated autocrine and paracrine mechanisms thatregulate malignant PCs growth and drug response, and support EDN1receptors as new therapeutic targets in MM

Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol \u3b1-bisabolol, a dual proapoptotic and antiautophagic agent

The sesquiterpene \u3b1-bisabolol (\u3b1-BSB) is a cytotoxic agent against acute leukemia and chronic myeloid leukemia cells. Here the profile of \u3b1-BSB citotoxicity was evaluated ex vivo in primary mononuclear blood cells isolated from 45 untreated B-chronic lymphocytic leukemia (B-CLL) patients. We studied the effects of \u3b1-BSB by flow cytometric and western blotting techniques with the following findings: (1) \u3b1-BSB was an effective proapoptotic agent against B-CLL cells (IC50 42 \ub1 15 \u3bcM). It was also active, but to a lesser extent, on normal residual B cells and monocytes (IC50 68 \ub1 34 and 74 \ub1 28 \u3bcM, respectively; p < 0.01), while T-cells, though not achieving IC50, were nevertheless decreased. (2) Lipid raft content positively correlated with \u3b1-BSB cell sensitivity, while neither the phenotype of B-CLL cells nor the disease clinical stage did affect the sensitivity to \u3b1-BSB. (3) Flow cytometry analysis evidenced the induction of pores in mitochondrial and lysosomal membrane after 3- to 5-hour exposure of B-CLL cells to \u3b1-BSB, leading to apoptosis; in contrast, western blotting analysis showed inhibition of the autophagic flux. Therefore, according to cellular selectivity, \u3b1-BSB is a cytotoxic agent preferentially active against leukemic cells, while its lower activity on normal B cells, monocytes and T cells may account for an additive anti-inflammatory effect targeting the leukemia-associated pro-inflammatory microenvironment. Consistent with the observed effects on intracellular processes, \u3b1-BSB should be regarded as a dual agent, both activating mitochondrial-based apoptosis and inhibiting autophagy by disrupting lysosomes

Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma

Splenic marginal zone lymphoma (SMZL) is a low-grade lymphoma showing a rather nonspecific immunophenotype. Gene expression profiling studies suggested that TCL1A could be a marker of SMZL, but reported data are conflicting. We evaluated TCL1A expression in a series of spleen and bone marrow samples involved by SMZL and correlated the findings with other immunophenotypical, morphological, and clinical data. In addition, we evaluated the expression of TCL1A in a series of spleens and lymph nodes involved by lymphomas that might mimic SMZL (13 nodal marginal zone lymphomas (NMZL), 39 follicular lymphomas (FL), 30 B-cell chronic lymphocytic leukemias (B-CLL), 31 mantle cell lymphomas (MCL), 1 lymphoplasmacytic lymphoma) and 15 bone marrow specimens involving hairy cell leukemia (HCL). TCL1A staining was negative in 24/31 cases of SMZL (77%); 27/31 MCL and all B-CLL were positive for TCL1A; 32/34 cases of nodal FL (96%) and all five splenic FL were positive for TCL1A, although at a lower intensity. Eight of 13 NMZL were positive for TCL1A, often showing a heterogeneous staining pattern. All HCL samples were strongly positive for TCL1A. No correlation was found between the pattern of splenic infiltration, TCL1A expression, and the clinical course. TCL1A-positive SMZL showed a higher rate of DBA44 staining compared to the negative ones, and this difference was statistically significant (Fisher test, single-tailed, p=0.0397). Our data support the use of TCL1A in the panel of diagnostic markers used in the differential diagnosis of splenic low-grade B-cell lymphoma; a possible prognostic value, however, needs a larger series to be established

In reply to Sch\ue4fer et\ua0al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma

no abstract availabl

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

No abstract availabl